Abstract
Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9
Current Pharmaceutical Design
Title:Advances in Biomarker Research for Pancreatic Cancer
Volume: 18 Issue: 17
Author(s): Kruttika Bhat, Fengfei Wang, Qingyong Ma, Qinyu Li, Sanku Mallik, Tze-chen Hsieh and Erxi Wu
Affiliation:
Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9
Abstract: Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Export Options
About this article
Cite this article as:
Bhat Kruttika, Wang Fengfei, Ma Qingyong, Li Qinyu, Mallik Sanku, Hsieh Tze-chen and Wu Erxi, Advances in Biomarker Research for Pancreatic Cancer, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092439
DOI https://dx.doi.org/10.2174/13816128112092439 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience Toll-Like Receptors and their Role in Hematologic Malignancies
Current Molecular Medicine Graphical Abstracts
Letters in Drug Design & Discovery Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Subject Index to Volume 2
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Role of Estradiol and Progesterone in HIV Susceptibility and Disease Progression
Mini-Reviews in Medicinal Chemistry Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe
Current Drug Metabolism Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics A New Synthetic Spiroketal: Studies on Antitumor Activity on Murine Melanoma Model In Vivo and Mechanism of Action In Vitro
Anti-Cancer Agents in Medicinal Chemistry Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Editorial [Hot Topic: Novel Kinase Inhibitors in Cancer Therapy (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Meta-heuristic Techniques to Train Artificial Neural Networks for Medical Image Classification: A Review
Recent Advances in Computer Science and Communications Novel Insights Into c-Src
Current Pharmaceutical Design